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Abstract  27 
Purpose. To examine the clinical impact of cardiorespiratory fitness (CRF) and 28 
improvements in CRF after cardiac rehabilitation (CR) in heart failure (HF) patients for their 29 
risk of all-cause mortality and unplanned hospitalization. Secondly, to investigate possible 30 
factors associated with the absence of improvement in CRF after rehabilitation. 31 
Methods. We included 155 HF patients receiving CR between October 2009 and January 32 
2015. Patients performed an incremental bicycle test to assess CRF through peak oxygen 33 
uptake (VO2-peak) before and after CR-based supervised exercise training. Patients were 34 
classified as responders or non-responders based on pre-to-post CR changes in VO2-peak 35 
(≥6% and <6%, respectively). Cox proportional hazards models evaluated all-cause mortality 36 
and unplanned hospitalization during 5 years of follow-up. Patient characteristics, HF features 37 
and co-morbidities were used to predict changes in VO2-peak using logistic regression 38 
analysis. 39 
Results. Seventy HF patients (45%) were classified as responder. Non-responders had a 40 
significantly higher risk of all-cause mortality or hospitalization (HR = 2.15, 95% CI = 1.17-41 
3.94) compared to responders. This was even higher in non-responders with low CRF at 42 
baseline (HR = 4.88, 95% CI = 1.71-13.93). Factors associated with non-response to CR were 43 
age (OR = 1.07/year, 95% CI = 1.03-1.11), baseline VO2-peak (OR = 1.16/ml/min/kg, 95% 44 
CI = 1.06-1.26) and adherence to CR (OR = 0.98/percentage, 95% CI = 0.96-0.998).  45 
Conclusion. Independent from baseline CRF, the inability to improve VO2-peak by CR 46 
doubled the risk of death or unplanned hospitalization. The combination of lower baseline 47 
CRF and non-response was associated with even poorer clinical outcomes. Especially older 48 
HF patients with higher baseline VO2-peak and lower adherence have a higher probability of 49 
becoming a non-responder.  50 
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INTRODUCTION 53 
Heart failure (HF) is diagnosed in 1-2% of the adult population of developed countries and is 54 
characterized by a structural or functional impairment of ventricular filling or ejection (1, 2). 55 
HF patients typically suffer from dyspnea and fatigue, which may limit their habitual physical 56 
activity and contribute to exercise intolerance. Hence, the cardiorespiratory fitness (CRF) of 57 
HF patients is lower compared to age- and sex-predicted reference values (3, 4). Previous 58 
studies indicated that CRF is an important predictor for the course of disease (5, 6), with 59 
lower CRF being related to an increased risk of cardiovascular events. Improvement of CRF 60 
through exercise training is therefore recommended in HF patients (1, 2).  61 
Previous studies in HF patients suggest a potential decline in mortality and 62 
hospitalization rate after standardized cardiac rehabilitation (CR; involving exercise training) 63 
compared to usual care (7, 8). However, significant heterogeneity exists in individual 64 
responses to CR, with some demonstrating no change or even a decline in fitness. It has been 65 
estimated that only half of the HF patients improve their fitness after standardized CR (9, 10), 66 
compared to 86% in non-HF individuals (11). Evidence is limited whether the absence of 67 
improvement affects future survival and morbidity. Preliminary work suggests that HF 68 
patients with an increased fitness after CR (responders) have a lower risk of all-cause 69 
mortality and hospitalization compared to patients without such improvements (non-70 
responders) (9). Likewise, non-responders demonstrated an increased risk of cardiac events 71 
compared to responders (10). These studies were, however, limited by a low adherence (40%) 72 
to the exercise training sessions. Moreover, the work related to a specific population of HF 73 
patients (i.e. young (systolic) HF patients) and relatively short follow-up (9, 10). Given the 74 
overall health benefits of CR-based exercise programs and the high number of non-75 
responders, it is relevant to better understand the clinical impact of being a non-responder and 76 
to identify HF patients who are at particular risk of becoming a non-responder.  77 
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Therefore, the aim of our study was to compare the risk of morbidity and all-cause 78 
mortality between HF patients responding and non-responding in CRF improvement after 79 
standardized and supervised exercise training as part of a CR program. We expect that 80 
improvement in CRF after rehabilitation is associated with a reduced risk of morbidity and all-81 
cause mortality, whilst this observation is independent of pre-rehabilitation levels of CRF. 82 
Furthermore, to better understand the characteristics of a non-responder, we aimed to predict 83 
which HF patients will become a non-responder to CR using personal-, health-, disease- and 84 
exercise training-related characteristics.  85 
 86 
METHODS 87 
Subjects 88 
All HF patients who followed supervised exercise training as part of a CR program at the 89 
Radboud university medical center or Isala Clinic between October 2009 and January 2015 90 
were eligible for participation in the study. Both patients with a reduced ejection fraction 91 
(HFrEF) and a preserved ejection fraction (HFprEF) were included if they performed a 92 
baseline and follow-up fitness test. HF patients with a peak respiratory exchange ratio (RER) 93 
<1.00 at baseline and/or post-training exercise test were excluded from the study to guarantee 94 
the quality of the included data. 95 
 96 
Experimental design 97 
At baseline and after completion of the exercise-training program, HF patients underwent 98 
cardiopulmonary exercise testing to determine changes in CRF. Absolute change in physical 99 
fitness was assessed by calculation of the difference in peak oxygen uptake (VO2-peak) 100 
between both exercise tests. Relative change was calculated by dividing the absolute change 101 
by the baseline VO2-peak. HF patients were classified as responder if they demonstrated a 102 
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relative improvement in VO2-peak ≥6% and as non-responder if the increase in VO2-peak was 103 
<6%. The threshold of 6% improvement was used to compensate for inter-test variability, and 104 
an increase of VO2-peak ≥6% was considered as a meaningful and reliable difference (12).   105 
Data related to patient characteristics, unplanned hospitalization and all-cause 106 
mortality were extracted from electronic patient files at both hospitals. The Local Committee 107 
on Research Involving Human Subjects of the region Arnhem and Nijmegen approved the 108 
study, and the study adhered to the Declaration of Helsinki. 109 
 110 
Exercise training programs 111 
HF patients participated in four different supervised exercise-training programs, depending on 112 
year of participation and the available program at the medical center. Patients from the 113 
Radboud university medical center participated in: 1) an 8-week exercise program, consisting 114 
of 2 sessions/week at a moderate exercise intensity (n=23); or 2) a 12- week exercise 115 
program, consisting of 2 sessions/week at moderate (n=10) or high exercise intensity (n=10). 116 
Patients from the Isala Clinic participated in 3) a 12-week exercise program, consisting of 2 117 
sessions/week at a moderate exercise intensity (n=36); or 4) a 24-week exercise program 118 
(n=76), consisting of 2 sessions/week at a moderate exercise intensity. Moderate intensity was 119 
defined as BORG score 11-15. During high intensity training sessions 10 bouts of 1-minute at 120 
90% of the maximal workload were alternated by 2.5 minutes at 30% of the maximal 121 
workload. Adherence of HF patients to the exercise program was defined as the total number 122 
of training sessions performed by a patient divided by the total number of training sessions in 123 
the program. This ratio was multiplied by 100 to obtain a percentage. 124 
 125 
 126 
 127 
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Cardiopulmonary exercise test  128 
Standardized exercise testing was performed on a bicycle ergometer with increasing workload 129 
until exhaustion. The oxygen consumption was measured by an automated system, which was 130 
calibrated before every test with both ambient air and a fixed known gas mixture. During 131 
exercise testing, subjects were verbally encouraged to achieve maximum exertion, evidenced 132 
by a RER ≥1.00. Respiratory gas analysis measured the oxygen uptake, carbon dioxide 133 
production, and ventilation. Gas exchange results were used to determine the VO2-peak, 134 
which was defined as the average VO2 over the last 30 seconds of the exercise test. The 135 
maximum heart rate and workload (Watt) were measured during the exercise test.  136 
 137 
Data extraction 138 
Electronic patient files were used to collect: 1) baseline patient characteristics including age, 139 
sex, body mass index (BMI), current smoking status and co-morbidities (diabetes mellitus, 140 
chronic obstructive pulmonary disease and hypertension), and 2) HF characteristics such as 141 
disease etiology (ischemic versus non-ischemic), New York Heart Association (NYHA) 142 
classification, left ventricular ejection fraction, history of atrium fibrillation, medication use 143 
(angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, beta blocker agent, 144 
aldosterone receptor antagonist, loop diuretic and statins), and the presence of medical 145 
devices (pacemaker, cardiac resynchronization therapy or implantable cardioverter 146 
defibrillator). Furthermore, we used all-cause unplanned hospitalization events and all-cause 147 
mortality as our end points and obtained these from the electronic patient files.  148 
 149 
Data analysis 150 
Kaplan–Meier curves and the log-rank test were used to assess the difference in clinical 151 
outcome between responders and non-responders. The end-point was any unplanned 152 
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hospitalization or all-cause mortality. Patients who did not reach the end-point were censored 153 
at the end of the observation period or after 5 years of follow-up. The follow-up started at the 154 
baseline cardiopulmonary exercise test prior to CR. The crude hazard rate ratio (HR) with 155 
95% confidence interval (CI) was calculated first by univariable Cox proportional hazards 156 
modelling. Subsequently, we compared patient characteristics, HF characteristics, medication 157 
use, medical devices and physiological variables between groups using the chi-squared test 158 
for categorical variables, Student’s t-test for normally distributed continuous variables and the 159 
Mann-Whitney U test for not normally distributed continuous variables. We adjusted the 160 
survival analysis with multivariable Cox proportional hazards modelling for the following 161 
possible confounding factors: age, sex, BMI, baseline VO2-peak and a cardiac 162 
resynchronization therapy combined with implantable cardioverter defibrillator. The adjusted 163 
HR was calculated with a 95% CI.  164 
To calculate the odds of becoming a non-responder, we used univariable logistic 165 
regression and examined the following factors: age, sex, BMI, current smoking status, co-166 
morbidities, disease etiology, NYHA classification, ejection fraction, history of atrium 167 
fibrillation, medication use and the presence of medical devices (pacemakers, cardiac 168 
resynchronization therapy or implantable cardioverter defibrillator), adherence, duration and 169 
type of the rehabilitation program, and baseline values of VO2-peak, maximum achieved heart 170 
rate and peak workload. The potential factors were entered into a hierarchical multivariable 171 
logistic regression model using different blocks. In all blocks, backward selection was used 172 
with stepwise removal at P = 0.10 to identify the most predictive variables. The 173 
discriminative performance of the model was assessed by calculating the area under the 174 
receiver operating characteristic curve (AUC).  175 
To calculate the necessary sample size, we performed a power calculation using a 176 
power of 80%, an overall type 1 error of 0.05 (two-sided), and as clinically relevant effect size 177 
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a hazard ratio of 2. Approximately 145 subjects were needed to obtain the number of required 178 
events (n=71)(13). To develop a prediction model, we use the rule of thumb with minimal 10 179 
events per variable for obtaining a good prediction(14, 15). Statistical analyses were 180 
performed in SPSS 20.0. A P < 0.05 was considered statistically significant. 181 
 182 
RESULTS 183 
Study population 184 
A total of 187 HF patients met the inclusion criteria of our study. After inspection for data 185 
quality, 32 patients were excluded due to a maximum RER<1.00 during the maximal exercise 186 
test. As a result 155 patients were available for analysis (Figure 1), with a median adherence 187 
to the supervised training sessions of 88% and inter-quartile range of 79%–96%.  188 
 189 
Responders versus non-responders 190 
Seventy HF patients (45%) were classified as responder (Supplemental Figure 1). Non-191 
responders were more frequently men, had a lower adherence to the rehabilitation program, a 192 
higher baseline VO2-peak and a lower post-training VO2-peak compared to responders (Table 193 
1). Age, BMI, current smoking behavior, and the duration of the rehabilitation program did 194 
not differ between the groups. Likewise, no differences in HF characteristics, co-morbidities, 195 
medication use, medical devices and other physiological data were found.  196 
 197 
All-cause mortality and unplanned hospitalization 198 
143 out of 155 HF patients were included in the survival analysis, as the follow-up data of 12 199 
patients were not accessible for data protection reasons. In total 57 HF patients died or had an 200 
unplanned hospitalization: 36 non-responders (46%) and 21 responders (33%). The median 201 
follow-up period was 23 months (inter-quartile range 13–47) for non-responders and 30 202 
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months (15–50) for responders. Figure 2 shows the Kaplan-Meier curves for time to 203 
unplanned hospitalization or death (P=0.12). Non-responders had a 52% higher risk of death 204 
or unplanned hospitalization than responders (HR = 1.52, 95% CI = 0.89-2.61). The 205 
multivariable Cox proportional hazards regression analysis showed that the risk of death or 206 
unplanned hospitalization was more than twice as high in non-responders (HR = 2.15, 95% CI 207 
= 1.17-3.94) after adjustment for age, sex, BMI, baseline VO2-peak and a cardiac 208 
resynchronization therapy combined with implantable cardioverter defibrillator. Subgroup 209 
analyses did not show any difference in results for patients with HFrEF or HFprEF at 210 
baseline.   211 
 A lower baseline CRF level (VO2-peak <16.5 ml/min/kg) was associated with a 2.76 212 
(95% CI = 1.52-5.05) increased risk of all-cause mortality and unplanned hospitalization after 213 
adjustment for age, sex, BMI and response status. Conversely, after adjustment for age, sex, 214 
BMI, and CRF level, non-responders had a 1.80 (95% CI = 1.02-3.18) higher risk of all-cause 215 
mortality and unplanned hospitalization. Non-responders with the lowest baseline CRF had a 216 
4.88 (95% CI = 1.71-13.93) higher risk of all-cause mortality or unplanned hospitalization 217 
compared to responders with a high baseline CRF level (Figure 3). 218 
 219 
Predicting response to exercise training 220 
We identified age, sex, etiology of HF, use of angiotensin-converting enzyme inhibitor or 221 
angiotensin II receptor blocker, loop diuretics, pacemaker, baseline VO2-peak and adherence 222 
to the exercise program as potential factors associated with becoming a non-responder to CR 223 
based exercise training (Supplemental Table 1). Multivariable logistic regression analysis 224 
revealed that HF patients of higher age (odds ratio [OR] = 1.07/year, 95 % CI = 1.03–1.11), 225 
higher baseline VO2-peak (OR = 1.16/ml/min/kg, 95% CI = 1.06–1.26) and adherence to the 226 
exercise program (OR = 0.98/percentage, 95% CI = 0.96–0.998) were associated with being a 227 
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non-responder. The performance of the prediction model is shown in Figure 4 and 228 
demonstrates an AUC of 0.73 (95% CI = 0.65–0.82). 229 
 230 
DISCUSSION 231 
As many as 55% of 155 HF patients did not increase VO2-peak following supervised exercise 232 
training sessions in a CR program. More importantly, HF patients classified as non-233 
responders to CR had a 2.15 times higher risk of all-cause mortality or unplanned 234 
hospitalization compared to responders after adjustment for possible confounders. The 235 
increased risk of all-cause mortality or unplanned hospitalization for non-responders was 236 
independent of pre-rehabilitation CRF levels. In addition, non-responders with lower CRF 237 
levels had the worst prognosis for unplanned hospitalization and all-cause mortality. Taken 238 
together, our data reinforce the clinical importance of baseline CRF levels and the ability to 239 
improve fitness after exercise training. In order to predict non-response to CR, we found that 240 
higher age, lower adherence and higher baseline VO2-peak were significant associated with of 241 
non-response status. 242 
 243 
Non-response, all-cause mortality and unplanned hospitalization  244 
We found that 85 HF patients (55% of study population) were classified as non-responders to 245 
exercise training. Although this prevalence is remarkably high, our findings are in line with 246 
most (50-56% non-responders) (9, 10), but not all (0.9% non-responders) (16), studies 247 
assessing changes in VO2-peak following CR. The conflicting outcomes are probably related 248 
to the definition of being a non-responder. For example, the study of Leifer et al. with a 249 
prevalence of 0.9% non-responders defined non-response as a decrease in VO2-peak ≥5 250 
ml/min/kg (16), whereas we and others (9, 10) defined non-response as a lack of increase in 251 
VO2-peak after exercise training. Nonetheless, our data provides further evidence that the 252 
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presence of non-responders in HF patients who participate in CR programs is larger than 253 
typically observed in a healthy patient cohort. 254 
In line with our observations, previous work found that HF patients benefit from 255 
exercise training (7, 17-19). Data from the HF-ACTION trial revealed a 5% higher risk for 256 
all-cause mortality or all-cause hospitalization in non-responders compared to responders 257 
after 3 years of follow-up (9). The benefits of VO2-peak improvement were much larger in 258 
our study population as we found a 2.15 higher risk (HR = 2.15, 95% CI = 1.17–3.94) for all-259 
cause mortality or unplanned hospitalization in non-responders versus responders after 5 years 260 
of follow-up. However, comparison between the HF-ACTION trial and this study is limited 261 
since HF-ACTION only included HFrEF patients and this study included both HFrEF and 262 
HRprEF. In addition, apart from a longer follow-up time, the difference in risk reduction 263 
between our study and HF-ACTION may also relate to study cohort characteristics. 264 
Compared to the HF-ACTION trial, our HF patients were more often classified as NYHA 265 
classification I or II, showed a lower prevalence of ischemic etiology, a higher baseline peak-266 
VO2 (16.5 versus 15.0 ml/min/kg), and had a relatively high adherence (median, 88%). These 267 
factors (i.e. lower NYHA classification, non-ischemic etiology (20), higher CRF (6)) are 268 
typically associated with better survival in HF patients. This suggests that less severe HF 269 
patients may have greater health benefits from CRF improvements following CR. Future 270 
studies are required to better understand this relation.  271 
 272 
In examining the benefits of cardiac rehabilitation it is important to take pre-273 
rehabilitation levels of fitness into consideration since previous work found that fitness may 274 
represent the strongest predictor for (all-cause) mortality and morbidity in HF patients (5, 6). 275 
In agreement with this previous research, we found that baseline fitness levels are strongly 276 
and independently related to mortality or hospitalization. Taking both baseline fitness and 277 
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change in fitness post-rehabilitation into consideration, we found that non-responders with 278 
lower fitness levels had the highest risk of adverse clinical outcomes. These data show for the 279 
first time that, both, lower baseline fitness levels and non-response to CR are independently 280 
and in combination associated with an increased risk of adverse events in HF patients.  281 
 282 
Prediction of non-response 283 
In this study we tried to identify factors that predict non-response to exercise training in HF 284 
patients, since this response is related to future adverse events. We demonstrated that older 285 
HF patients with a relatively high baseline VO2-peak and lower adherence were more often 286 
non-responders. These findings align with observations from other studies. A meta-analysis in 287 
HF patients showed that lower age was associated with larger improvements of VO2-peak 288 
(21). Also, HF patients higher VO2-peak (22, 23) had smaller improvements in fitness 289 
following exercise training. Medication use was not associated with response status and did 290 
not significantly change during CR within both groups. Therefore, we do not expect an 291 
interaction of medication in relation to performance outcomes. Our prediction model had an 292 
AUC of 0.73, which indicates that the discriminative power of our model is not sufficient for 293 
direct implementation in clinical practice. Nonetheless, we have identified factors that 294 
significantly contribute to the prediction whether CRF improves after training. The addition of 295 
chonotropic incompetence (24) and parameters reflecting severe hemodynamic dysfunction 296 
(25, 26) and cardiac dimensions (27, 28) may further improve its predictive capacity and 297 
warrant further investigation.  298 
 299 
Clinical relevance  300 
The observation that non-response to CR training is related to increased all-cause mortality or 301 
hospitalization has important clinical consequences. Independent of baseline fitness levels, the 302 
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inability to improve fitness after exercise training increases the risk for adverse events. 303 
Especially non-responders with lower baseline fitness are at high risk for adverse events. This 304 
further emphasizes the importance of non-response in CR. Non-modifiable factors (age, 305 
baseline VO2-peak) contribute to early identification, which may lead to the prescription of a 306 
different type of CR. For example, non-responders might benefit from other types of exercise 307 
interventions such as high intensity interval training or resistance training to improve their 308 
physical fitness. Literature revealed that HF patient performing high or vigorous intensity 309 
exercise programs have an higher increase in the peak VO2 compare to moderate intensity 310 
programs (17, 29) and are less likely to show a non-response to training. Resistance exercise 311 
improves muscle mass, strength and muscular fitness in HF patients (30-32) and therefore 312 
might increase cardiovascular fitness by optimizing the response to aerobic conditioning. In 313 
fact, the combination of aerobic and resistance exercise training appeared to be superior for 314 
improving submaximal exercise capacity and health-related quality of life compared to 315 
aerobic exercise only (33). In addition, HF patients who remain to be non-responders, may 316 
have to increase training frequency (34). Such approaches may contribute to a reduction of 317 
future adverse events in this vulnerable group. Finally, strong adherence to exercise training 318 
should be encouraged in HF patients, since adherence is a significant and, more importantly, 319 
modifiable factor for being a non-responder to CR. 320 
 321 
Strengths and limitations 322 
This study included typical HF outpatients, which increases the external validity of our study. 323 
In addition, there were no drop-outs during follow-up which means that all censoring was 324 
non-informative and therefore unrelated to patient prognosis. A limitation of our study may 325 
relate to the exclusion of 17% of eligible HF patients due to an insufficient RER during the 326 
exercise test. However, to guarantee the quality of the achieved maximal VO2 and thereby the 327 
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stratification into responder versus non-responder, it was inevitable to exclude those patients. 328 
Furthermore, it was not feasible to use standardized meals before exercise testing. Also, no 329 
data was available about diet or water consumed before the exercise test, which may influence 330 
the VO2-peak. 331 
 332 
CONCLUSIONS 333 
Non-responders to exercise training had a 2.15 higher risk of all-cause mortality or unplanned 334 
hospitalization compared with responders after adjustment for possible confounders, a finding 335 
independent from other prognostic markers for adverse events (including baseline levels of 336 
fitness). This observation is of clinical importance since half  of the HF patients participating 337 
in a CR-based supervised exercise training program was unable to significantly improve VO2-338 
peak. Higher age and baseline VO2-peak, and lower adherence were identified as independent 339 
factors associated with non-response to CR-based exercise training in HF patients. 340 
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TABLES 453 
Table 1. Characteristics of 155 heart failure patients according to their response to cardiac 
rehabilitation. 
 Responders 
N=70 
Non-responders  
N= 85  
P-value 
Patient characteristics    
Age (years) 61 (53−67) 63 (55−71) .09 
Sex (male)  47 (67%) 69 (81%) .045 
BMI (kg/m2) 28 (SD 5.8) 29 (SD 5.0) .40 
Smoking (current) 16 (23%) 16 (19%) .54 
Diabetes mellitus (yes)  12 (17%) 9 (11%) .24 
COPD (yes) 6 (9%) 9 (11%) .67 
Hypertension (yes)  26 (37%) 38 (45%) .34 
Heart failure characteristics    
Aetiology, ischemic  24 (34%) 40 (47%) .11 
Baseline NYHA  
I-II 
III-IV 
 
47 (67%) 
16 (23%) 
 
63 (74%) 
18 (21%) 
.66 
Baseline LVEF  
worse (<30%)  
moderate (30-45%) 
reasonable (45-55%) 
good (>55%) 
 
20 (28%) 
14 (20%) 
3 (4%) 
18 (26%) 
 
21 (25%) 
19 (22%) 
3 (4%) 
27 (32%) 
.79 
Atrium fibrillation (yes) 20 (29%) 27 (32%) .67 
 23 
 
Medication use    
ACEI or ARB 64 (93%) 83 (98%) .15 
Beta blocker agent 64 (91%) 75 (88%) .52 
Aldosteron receptor antagonist  14 (20%) 18 (21%) .86 
Loop diuretic  61 (87%) 68 (80%) .23 
Statin 41 (58%) 52 (61%) .74 
Medical devices    
ICD-CRT  13 (19%) 22 (25%) .26 
Pacemaker  10 (14%) 16 (19%) .44 
CRT 1 (1%) 1 (1%) .90 
ICD  15 (21%) 19 (22%) .87 
Rehabilitation program    
Type of rehabilitation 
MIT  
HIT  
 
64 (91%) 
6 (9%) 
 
81 (95%) 
4 (5%) 
.36 
Duration of rehabilitation 
(weeks) 
20 (12-26) 13 (12-26) .79 
Adherence to exercise program 
(%)* 
91 (81-100) 83 (75-96) .028 
Physiological parameters    
Baseline VO2-peak 
(ml/min/kg) 
15.2 (13.1−18.6) 16.9 (14.1−20.9) .025 
Post VO2-peak (ml/min/kg) 18.8 (15.5−21.9) 15.9 (12.8−19.7) .017 
Difference VO2-peak(ml/min) 224 (162−359) -43 (-136−31) <.001 
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Baseline max. heart rate 
(beats/min) 
125 (110−143) 127 (109−144) .98 
Post max. heart rate 
(beats/min) 
129 (113−149) 126 (110−139) .13 
Baseline max. cycle load 
(Watt) 
107 (77−142) 116 (89−149) .08 
Post max. cycle load (Watt) 130 (87−165) 120 (88−150) .35 
Baseline RER  1.16 (1.09−1.22) 1.16 (1.08−1.25) .90 
Post RER  1.15 (1.08−1.22) 1.17 (1.09−1.25) .22 
Data is presented in n (%) unless indicated as mean (SD) and median (Q25−Q75). 
*Data was only available in 135 patients.  
BMI = body mass index, COPD = chronic obstructive pulmonary disease, NYHA = New 
York Heart Association functional classification, LVEF = left ventricular ejection fraction, 
ACEI = angiotensin-converting enzyme inhibitor, ARB=angiotensin II receptor blocker, 
ICD = implantable cardioverter defibrillator, CRT = cardiac resynchronization therapy, 
MIT= moderate intensity training, HIT=high intensity training, VO2-peak = peak oxygen 
consumption max.=maximal and RER=respiratory exchange ratio. 
  454 
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FIGURES 455 
 456 
Figure 1. Flowchart of the inclusion of 155 heart failure patients from Radboud university 457 
medical center and Isala Clinic. The study population consisted of 187 HF patients who met 458 
the inclusion criteria. After inspection for data quality, 32 patients were excluded due to a 459 
maximal respiratory exchange ratio <1.00 during the exercise test. The final study population 460 
comprised 70 responders and 85 non-responders.   461 
 462 
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 463 
Figure 2. Kaplan-Meier curves of the time to death or unplanned hospitalization in 143 heart 464 
failure patients. In total 57 HF patients were hospitalized or died during follow-up: 36 non-465 
responders (46%) and 21 responders (33%). The crude 5-year probability for all-cause 466 
mortality or unplanned hospitalization was 41% for responders and 56% for non-responders 467 
(log-rank test P=.12). 468 
 469 
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 470 
Figure 3. Hazard ratios of all-cause mortality or unplanned hospitalization by baseline fitness 471 
levels and response to CR. The dots present hazard ratios (95% confidence intervals). Higher 472 
fitness was defined as baseline VO2-peak >16.5 ml/min/kg and lower fitness as VO2-peak 473 
≤16.5 ml/min/kg. Hazard ratios were adjusted for age, sex and BMI.  474 
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 475 
Figure 4. Discriminative performance of the prediction model for non-response to exercise 476 
training. The prediction model included age, baseline peak-VO2 and adherence to the exercise 477 
program. The receiver operating characteristic curve had an area under the curve of 0.73 (95% 478 
CI = 0.65–0.82).  479 
  480 
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SUPPLEMENTAL MATERIAL MSSE 481 
 482 
Supplemental Table 1. Predictors of non-response to exercise training in 155 
heart failure patients using univariate logistic regression. 
Parameters Odds 
ratio 
95% CI  P-value 
Patient characteristics    
Age (median, years) 1.03 1.00-1.05 .07 
Sex (male)  0.47 1.01-4.41 .05 
BMI (kg/m2) 1.03 0.97-1.09 .40 
Smoking (current) 0.78 0.34-1.71 .54 
Diabetes mellitus (yes)  0.57 0.23-1.45 .24 
COPD (yes) 1.26 0.43-3.74 .67 
Hypertension (yes)  1.37 0.72-2.61 .34 
Heart failure characteristics    
Aetiology, ischemic  1.70 0.89-3.27 .11 
Baseline NYHA (I-II) 1.19 0.55-2.58 .66 
Baseline LVEF  
worse (<30%)  
moderate (30-45%) 
reasonable (45-55%) 
good (>55%) 
 
0.70 
0.91 
0.67 
REF 
 
0.30-1.65 
0.36-2.25 
0.12-3.68 
 
.41 
.83 
.64 
Atrium fibrillation (yes) 1.16 0.58-2.32 .67 
Medication use    
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ACEI or ARB 3.24 0.61-17.25 .17 
Beta blocker agents 0.58 0.19-1.80 .35 
Aldosteron receptor antagonist  1.06 0.48-2.31 .89 
Loop diuretics  0.53 0.21-1.30 .16 
Statins 1.07 0.56-2.06 .83 
Medical devices    
ICD-CRT  1.55 0.72-3.38 .27 
Pacemaker  1.71 0.89-3.28 .11 
CRT 1.51 0.71-3.22 .29 
ICD  1.46 0.77-2.79 .25 
Rehabilitation program    
Type of rehabilitation* 
MIT  
HIT  
 
1.90 
REF 
 
0.51-7.01 
 
.34 
 
Duration of rehabilitation (weeks) 0.99 0.95-1.04 .76 
Adherence to exercise program (%)† 0.98 0.97-1.00 .06 
Physiological parameters    
Baseline VO2-peak (ml/min/kg) 1.07 1.01-1.14 .03 
Baseline max. heart rate (beats/min)‡ 1.00 0.99-1.01 .91 
Baseline max. cycle load (Watt)‡ 1.01 0.99-1.01 .07 
*excluded in multivariable model due to low numbers. 
†data was only available in 135 patients. 
‡excluded in multivariable model due to high correlation with VO2-peak. 
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BMI = body mass index, COPD = chronic obstructive pulmonary disease, NYHA= 
New York Heart Association classification, LVEF = left ventricular ejection 
fraction, ACEI = angiotensin-converting enzyme inhibitor, ARB=angiotensin II 
receptor blocker, ICD = implantable cardioverter defibrillator, CRT = cardiac 
resynchronization therapy, MIT= moderate intensity training, HIT=high intensity 
training, REF= reference, VO2-peak = peak oxygen consumption, max.= maximal 
and RER=respiratory exchange ratio. 
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Supplemental Figure 1. Relative difference in VO2-peak (%) between baseline and post 484 
exercise training values. Responders are presented in dark grey and non-responders in light 485 
grey. The dashed line represents a 6% improvement in VO2-peak, which was the cut-point for 486 
being a responder or non-responder.  487 
 488 
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